Patent details
93277 Product Name: Elotuzumab
Basic Information
- Publication number:
- 93277
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP078407467
- Legal Status:
- Inactive
- Application number:
- 93277
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/16/1088
- Marketing Authorization Type:
- Marketing Authorization Date:
- 13/05/2016
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
Dates
- Filing date:
- 24/10/2016
- First Marketing Authorization date:
- 13/05/2016
- Grant date:
- 27/12/2016
- Activation date:
- Publication date:
- 27/12/2016
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 13/05/2031
- SPC Extension Expiration:
- 13/05/2031
- Rejection date:
- Withdrawal date:
Owner
- From:
- 24/10/2016
- Name:
- ABBVIE BIOTHERAPEUTICS INC.
- Address:
- 1500 SEAPORT BOULEVARD, REDWOOD CITY, CA 94063, United States (US)
- Name:
- DANA-FARBER CANCER INSTITUTE, INC.
- Address:
- 450 BROOKLINE AVENUE, BOSTON, MA 02215, United States (US)
Agent
- Name:
- DENNEMEYER & ASSOCIATES S.A. PATENT DEPARTMENT
- From:
- 24/10/2016
- Address:
- PO Box 1502, 1015, LUXEMBOURG, Luxembourg (LU)
- To:
Inventor
1
- Name:
- AFAR Daniel
- Address:
- United States (US)
2
- Name:
- TAI Yu-Tzu
- Address:
- United States (US)
3
- Name:
- ANDERSON Kenneth, C.
- Address:
- United States (US)
Annual Fees
- Annual Fee Due Date:
- 31/08/2027
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|